Official media partner of business and marketing eventsEvents calendar

US
- NasdaqClosed26,702.86+278.04+1.05%, up
- Nasdaq 100Closed29,822.52+332.24+1.13%, up
- S&P 500Closed7,757.17+44.60+0.58%, up
- Dow 30Closed52,856.09+360.19+0.69%, up
- Russell 2000Closed2,781.02+7.60+0.27%, up
- VIXOpen17.98+1.30+7.79%, up
EuropeOpen
- FTSE 10010,737.02−15.86−0.15%, down
- DAX25,484.67−160.37−0.63%, down
- CAC 407,839.53−82.15−1.04%, down
AsiaClosed
- Nikkei 22562,907.84−1,713.40−2.65%, down
TürkiyeOpen
- BIST 10011,344.62−232.50−2.01%, down
Currencies
- EUR/USD1.1208−0.0027−0.24%, down
- GBP/USD1.3376−0.0018−0.13%, down
- USD/JPY157.12−0.94−0.59%, down
- USD/TRY49.6224+0.00210.00%, unchanged
Commodities
- Gold4,093.50−56.50−1.36%, down
- Brent111.77+2.95+2.71%, up
- WTI99.30+2.15+2.21%, up
Crypto
- Bitcoin81,702.03−1,696.32−2.03%, down

Delayed data· Yahoo FinanceUpdated 8:51 AM EDT

Loading market data

Science

Research, discovery, and the industries being built on them.

Science

Novo’s $1.4 Billion Bet on the Future of Oral Drugs

Novo Nordisk is backing Orbis Medicines in a deal worth up to $1.4 billion, betting that AI-enabled drug discovery can help turn traditionally injectable treatments into oral medicines.

Sep 20, 2026, 11:10 AM EDT

Key Terms

VANTAGE52 Glossary